Shopping Cart
- Remove All
- Your shopping cart is currently empty
(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), which can be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner, enhancing the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, thereby increasing survival time.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $158 | 35 days | |
50 mg | $265 | 35 days | |
100 mg | $488 | 35 days | |
250 mg | $748 | 35 days |
Description | (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), which can be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner, enhancing the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, thereby increasing survival time. |
Molecular Weight | 217.02 |
Formula | C6H5BrN2O2 |
Cas No. | 69304-49-0 |
Relative Density. | 1.881 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMF: 60 mg/mL (276.47 mM), Sonication is recommended. PBS (pH 7.2): 8 mg/mL (36.86 mM), Sonication is recommended. DMSO: 53 mg/mL (244.22 mM), Sonication is recommended. Ethanol: 0.8 mg/mL (3.69 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||||||||||||
Ethanol/PBS (pH 7.2)/DMSO/DMF
PBS (pH 7.2)/DMSO/DMF
DMSO/DMF
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.